Biotech Values

[DewDiligence]

SRNE licenses 4 FoB programs from China’s Mabtech:

http://finance.yahoo.com/news/sorrento-licenses-four-stage-clinical-100000760.html

Under the terms of the agreement, Sorrento will develop and market these 4 monoclonal antibodies (mAbs) for the North American, European and Japanese market.

Each of the mAbs has completed a Phase III study; two are currently in registration for marketing approval in China, while the other two are under data analyses for subsequent NDA submission in China. One of the biobetter mAbs is based on a Top 10-selling oncology drug and the other a Top 5-selling antibody to treat auto-immune diseases.

Financial terms and the identities of the four programs have not been disclosed.